

A⁷
30. A DNA molecule according to claim 28 when administered by particle bombardment.

A⁷
31. A DNA molecule according to claim 28 for use in achieving an increased immune response.


D⁶
32. A method of therapeutic or prophylactic vaccination comprising administering an effective amount of a DNA molecule as claimed in claim 1.

A⁸
34. A method according to claim 32 for use in achieving an increased immune response.

REMARKS

Currently claims 1-34 are pending. Claims 3-10, 16, 18-21, 25-28, 30-32 and 34 have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Elizabeth Selby
Attorney for Applicants
Registration No. 38,298

Date: September 11, 2001

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Telephone: (919) 483-3934
Facsimile: (919) 483-7988

Marked-Up Copy of Pending Claims

3. (Amended) A DNA molecule according to claim 1 [**or 2**] wherein said untranslated region has a ΔG of below -10kCal/mol.

4. (Amended) A DNA molecule according to claim 1 [**any preceding claim**] wherein said sequence has a ΔG that is below -30kCal/mol.

5. (Amended) A DNA molecule according to claim 1 [**any preceding claim**] wherein said sequence has a ΔG that is below -40kCal/mol.

6. (Amended) A DNA molecule according to claim 1 [**any preceding claim**] wherein said untranslated region has a ΔG of below -50kCal/mol.

7. (Amended) A DNA molecule according to claim 1 [**any preceding claim**] wherein expression of said polypeptide is heat shock responsive.

8. (Amended) An RNA molecule obtainable by transcribing a DNA molecule according to claim 1[**any of claims 1 to 7**].

9. (Amended) A vector comprising a DNA molecule according to claim 1[**any of claims 1 to 7**].

10. (Amended) An expression system comprising a DNA molecule according to claim 1 [**any of claims 1 to 7**], or a vector comprising said DNA molecule [**according to claim 9**].

16. (Amended) A method of obtaining a polypeptide comprising expressing the polypeptide using an expression system according to claim 10 [**any of claims 10 to 15**] and, optionally, purifying the polypeptide.

18. (Amended) A method of treating a deficiency in the expression of a polypeptide, comprising providing a patient with a DNA molecule as claimed in claim 1 [**any of claims 1 to 7**] which encodes said polypeptide, a vector [**as claimed in claim 9**] comprising said DNA molecule, or a cell comprising said DNA molecule or vector.

19. (Amended) A method of treating a deficiency in the expression of a polypeptide, comprising providing a patient with a DNA molecule as claimed in claim 1 [**any one of claims 1 to 7**] wherein said molecule is provided in a manner to allow it to become operably linked with a sequence already present in the patient which encodes said polypeptide.

20. (Amended) A method of treating a disorder (e.g. an infection) treatable by providing an increased immune response, comprising providing a patient with a vaccine comprising a DNA molecule as claimed in claim 1 [**any of claims 1 to 7**] or a vector comprising said DNA molecule [**as claimed in claim 9**].

21. (Amended) A method according to claim 18 [**or 19**], wherein a DNA molecule or vector is provided under conditions allowing it to integrate within the patient's genome.

25. (Amended) A pharmaceutically acceptable composition comprising a DNA molecule according to claim 1 [**any of claims 1 to 7**], an RNA molecule obtainable by transcribing said DNA molecule [**according to claim 8**], or an expression system comprising said DNA molecule [**a cell as described in claim 11**].

26. (Amended) A vaccine comprising a DNA molecule according to claim 1 [**any of claims 1 to 5**], or a vector comprising said DNA molecule [**according to claim 9**].

27. (Amended) The use of a DNA molecule according to claim 1 [**any of claims 1 to 7**], of an RNA molecule obtainable by transcribing said DNA molecule [**according to claim 8**], of a vector comprising said DNA molecule [**according to claim 9**], or of an expression system comprising said DNA molecule [**according to claim 10**], in achieving increased expression of a polypeptide.

28. (Amended) A DNA molecule according to claim 1 [**any one of claims 1 to 7**] for use in therapy.

30. (Amended) A DNA molecule according to claim 28 [**or 29**] when administered by particle bombardment.

31. (Amended) A DNA molecule according to claim 28[**, 29 or 30**] for use in achieving an increased immune response.

32. (Amended) A method of therapeutic or prophylactic vaccination comprising administering an effective amount of a DNA molecule as claimed in claim 1[**any one of claims 1 to 7**].

34. (Amended) A method according to claim 32 [**or 33**] for use in achieving an increased immune response.

TODAY'S DATE: 12/20/01